The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study

J Neurol Sci. 2016 Sep 15:368:150-4. doi: 10.1016/j.jns.2016.07.003. Epub 2016 Jul 2.

Abstract

Introduction: In Parkinson's disease patients, impulse control disorders (ICDs) have been associated with younger age and early disease onset, yet the prevalence of ICDs in early-onset Parkinson's disease (EOPD) patients has yet to be studied. Thus, we set out to compare the prevalence of impulse control behaviors (ICBs) in a cohort of EOPD patients with that in age and gender matched healthy controls (HCs), as well as to analyze the association of these symptoms with the use of dopaminergic drugs and other clinical or demographic factors.

Methods: A cross-sectional, multicenter study was carried out on patients recruited from outpatient Movement Disorder Clinics, assessing ICBs using the short form of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP). In addition, depression and quality of life (QoL) were measured, along with other demographic and clinical variables.

Results: Of the 87 EOPD patients, 49 (58.3%) displayed an ICB, as did 28 of the 87 HCs (32.9%; p=0.001). Most of the EOPD patients that displayed an ICB (91.8%) were medicated with a dopamine agonist (DA) and accordingly, DA treatment was associated with a 7-fold increased risk of developing an ICB. Patients with ICBs had a higher depression score and a worse QoL.

Conclusions: ICBs are much more prevalent in EOPD patients than in HCs and they are associated with DA intake, depression and a worse QoL.

Keywords: Dopamine agonist; Early-onset; Impulse control behavior; Impulse control disorders; Parkinson's disease; Quality of life.

Publication types

  • Multicenter Study

MeSH terms

  • Age of Onset
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / therapeutic use
  • Cohort Studies
  • Cross-Sectional Studies
  • Disruptive, Impulse Control, and Conduct Disorders / complications
  • Disruptive, Impulse Control, and Conduct Disorders / epidemiology*
  • Dopamine Agonists / adverse effects
  • Dopamine Agonists / therapeutic use
  • Female
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Parkinson Disease / complications
  • Parkinson Disease / drug therapy
  • Parkinson Disease / epidemiology*
  • Parkinson Disease / psychology
  • Prevalence
  • Quality of Life
  • Risk
  • Severity of Illness Index

Substances

  • Antiparkinson Agents
  • Dopamine Agonists